Dr. Robert Berman

Dr. Robert Berman first discovered the antidepressant effects of ketamine in humans alongside Dr John Krystal in 1990s at Yale. For over 20 years he has worked within the industry, first at Pfizer and then Bristol-Myers Squibb in clinical development roles, including leading the program for aripiprazole in depression, for which he developed novel clinical trial design that achieved three out of three highly statistically significant trials. In 2013, Rob co-founded Biohaven Pharmaceuticals (NYSE:BHVN) and was Chief Medical Officer until 2019.